Hyper-IgM Immunodeficiency Syndrome, Type 1 - 13 Studies Found
Completed |
: Study of Immune Responses and Safety of Recombinant Human CD40 Ligand in Patients With X-Linked Hyper-IgM Syndrome : Immunoproliferative Disorder : 1999-11-03 :
|
Terminated |
: Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States :
: 2005-12-16 |
Completed |
: Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases :
|
Completed |
: Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders :
|
Completed |
: A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency :
|
Recruiting |
: Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies :
: |
Completed |
: Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects : Primary Immune Deficiency Disease : 2008-03-05 : Biological: Flebogamma 5% DIF Intravenous Immune Globulin (Human) |
Active, not recruiting |
: Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) :
: Biological: Hematopoietic Stem Cell Transplant NOTE: The - |
Completed |
: A Clinical Study of Intravenous Immunoglobulin : Immunologic Deficiency Syndromes : 2007-05-01 : Drug: Immune Globulin Intravenous (Human) Omr-IgG-am IGIV IGIV infusions of 300-900 mg/kg every 3 or 4 w |